Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early
setting of breast cancer, there is a clinical need for predictive markers of response in daily …

Neoadjuvant chemotherapy was initially used only as treatment for locally advanced breast
cancer. However, because breast cancer is considered to be a systemic disease in which …

Preoperative or neoadjuvant chemotherapy is an option in patients with early-stage breast
cancer. Neoadjuvant treatment has been compared with standard, postoperative adjuvant …

Neoadjuvant therapy, where patients receive systemic therapy before surgical removal of
the tumour, can downstage tumours allowing breast-conserving surgery, rather than …

Currently, neoadjuvant chemotherapy is a standard therapeutic strategy for breast cancer,
as it can provide timely and individualized chemo-sensitivity information and is beneficial for …

Simple Summary Breast cancer is the most common cancer in women worldwide. Although
many studies have aimed to understand the genetic basis of breast cancer, leading to …

The post-neoadjuvant setting in early breast cancer represents an attractive scenario for
adjuvant clinical trials, offering the opportunity to test new drugs or combinations in high-risk …

Background: Early clinical response to neoadjuvant chemotherapy (NACT) in breast cancer
correlates with pathological response at surgery. A tailored approach using biomarkers to …

Neoadjuvant trials for early breast cancer have accelerated the identification of novel active
agents, enabling streamlined conduct of registration trials with fewer subjects. Measurement …

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be
assessed depending on molecular subtype, and to judge the impact of response to therapy …